AbbVie Inc.ABBV
AbbVie Inc. Financial Overview 2021–2025
Updated Jul 10, 2026Even as its former flagship drug Humira suffered a staggering 49.5% revenue collapse in FY2025, AbbVie expanded its total top line by 8.6% to reach $61.2 billion. The pharmaceutical giant has successfully bridged the industry's most anticipated patent cliff by aggressively pivoting its core immunology business toward two hyper-growth replacement assets.
This portfolio transition allowed total net revenue to grow from $56.2 billion in FY2021 to $61.2 billion in FY2025, definitively absorbing the biosimilar shock. By the end of this period, next-generation treatments Skyrizi and Rinvoq collectively accounted for roughly 42% of total revenues, posting massive year-over-year increases of 49.9% and 39.1% in FY2025. The company fueled this commercial shift with $19.0 billion in operating cash flow during the year, deploying capital toward strategic acquisitions like ImmunoGen and Cerevel Therapeutics to rebuild its oncology and neuroscience pipelines.
These aggressive pipeline investments and acquisition-related milestone expenses heavily compressed bottom-line profitability, dropping reported earnings to just $2.36 per share. Investors largely looked past this margin compression in favor of the successful revenue replacement. At the close of FY2025, the market valued the stock at $228.49, trading at a steep 96.8x earnings multiple as the company proved its new assets could carry the weight of the broader portfolio.
Recent Developments (Q4 2025 and Q1 2026)
In Q1 2026, AbbVie sustained its momentum with net revenues increasing 12.4% year-over-year to $15.0 billion. The immunology division remained the primary growth engine, with Skyrizi and Rinvoq revenues climbing 30.9% and 23.3%, respectively. The company optimized its capital structure by issuing $8.0 billion in senior notes in March 2026 to refinance a $2.0 billion term loan. AbbVie also absorbed a $744 million acquired IPR&D expense tied to an upfront license agreement payment with RemeGen.
Bulls highlight the diversified portfolio generating $3.8 billion in first-quarter operating cash flow. Conversely, bears note that aggressive pipeline investments pushed R&D expenses up 20% year-over-year to $2.5 billion, slashing quarterly earnings from $0.72 to just $0.39 per share. The stock remains richly valued at 85.4x earnings as of May 8, 2026, reflecting a continued market premium for its ongoing portfolio transition.
What to watch: clinical progress for RemeGen licensed assets; integration and pipeline impact of the upcoming Apogee Therapeutics acquisition.
Rev
$61.16B
FY2025
NI
$4.23B
FY2025
EPS
$2.37
FY2025
OCF
$19.03B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
All ABBV Financial Metrics(60)
Income Statement
Balance Sheet
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Accrued Liabilities
- Short-Term Debt
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- NCI
- Total L&E
Cash Flow
Recent SEC Filings
AbbVie Inc. 8-K Report, Regulation FD Disclosure (Sep 3, 2026)
AbbVie Inc. (ABBV) announced on September 3, 2026, the successful completion of its acquisition of Apogee Therapeutics, Inc. This strategic move signifies AbbVie's commitment to expanding its pipeline and potential future revenue streams through targeted acquisitions. Investors should focus on the implications of this acquisition for AbbVie's long-term growth prospects, particularly concerning the integration of Apogee's assets and their contribution to the company's future earnings. The company also provided forward-looking statements regarding its 2026 full-year and third-quarter adjusted diluted EPS guidance, hinting at the expected financial impact of this acquisition. While the full details of the financial statements and exhibits are incorporated by reference, the core message is the completion of a significant strategic transaction aimed at bolstering AbbVie's therapeutic portfolio.
AbbVie Inc. 8-K Report, Corporate Update (Aug 18, 2026)
AbbVie Inc. (ABBV) has announced the successful completion of a substantial underwritten public offering of notes totaling $9.75 billion on August 18, 2026. This comprehensive financing effort includes a mix of senior floating rate notes due 2028 and various fixed-rate senior notes with maturities ranging from 2028 to 2066 and coupon rates from 4.500% to 6.100%. The proceeds from this offering are earmarked primarily to fund a portion of the acquisition of Apogee Therapeutics, Inc., with any remaining funds to be used for general corporate purposes. This significant debt issuance underscores AbbVie's strategic move to finance a key acquisition, demonstrating a commitment to growth through M&A. Investors should note the substantial principal amount raised and the diverse maturity profile of the notes. The filing also details certain redemption provisions and covenants associated with these new debt instruments, as well as a special mandatory redemption clause contingent on the completion of the Apogee acquisition.
AbbVie Inc. 8-K Report, Corporate Update (Aug 5, 2026)
AbbVie Inc. (ABBV) announced through an 8-K filing on August 5, 2026, the closing of a significant debt offering totaling approximately $9.93 billion in net proceeds. This substantial capital raise comprises multiple tranches of senior notes with varying maturities and interest rates, including floating rate notes, fixed-rate notes ranging from 2028 to 2066. The primary purpose of this offering is to fund a portion of the cash payment obligations related to AbbVie's acquisition of Apogee Therapeutics, Inc. This strategic move underscores AbbVie's commitment to its growth strategy through significant M&A activity. The proceeds will also be used for other general corporate purposes, potentially including debt repayment or repurchase, and will reduce commitments under an existing term loan facility established for the Apogee acquisition.
AbbVie Inc. 8-K Report, Financial Results (Jul 31, 2026)
AbbVie Inc. (ABBV) filed an 8-K on July 31, 2026, to report its financial results for the second quarter ended June 30, 2026. The key takeaway for investors is the release of the company's quarterly earnings, which are detailed in an accompanying press release furnished as Exhibit 99.1. This filing serves as the official channel for disseminating AbbVie's performance metrics, including revenue, profitability, and any forward-looking statements or guidance the company chose to provide for the upcoming periods. Investors should review the press release carefully to understand the drivers of AbbVie's financial performance during the second quarter. This includes an examination of key product sales, any significant clinical development updates that may impact future revenue streams, and the company's overall financial health. The 8-K itself is a procedural filing, but the furnished press release contains the substantive financial and operational information crucial for investment decisions.
AbbVie Inc. 8-K Report, Financial Results (Jul 6, 2026)
AbbVie Inc. (ABBV) has filed an 8-K detailing preliminary second-quarter 2026 financial expectations, specifically addressing the impact of acquired In-Process Research and Development (IPR&D) and milestones expense. The company anticipates a pre-tax charge of $291 million related to these expenses, which is expected to negatively impact both GAAP and adjusted non-GAAP diluted earnings per share by $0.17 each. While these are preliminary estimates and subject to final financial closing procedures, investors should note this significant expense impacting near-term profitability. Despite the unfavorable impact from acquired IPR&D and milestones, AbbVie has reaffirmed its full-year 2026 adjusted diluted earnings per share guidance, now projected to be between $13.91 and $14.11. This revised guidance range incorporates the estimated second-quarter expense. The company also provided a specific second-quarter 2026 adjusted diluted earnings per share guidance range of $3.57 to $3.61, which also includes this expense. Investors are reminded that acquired IPR&D and milestones are inherently unpredictable and are not typically forecasted beyond the initial quarter they are incurred.
View all 8-K filings →